Medtronic Limited (MDT) Completes Enrollment in Global Head-to-Head Stent-Safety Study
2/2/2009 10:40:07 AM
MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced the completion of enrollment in PROTECT,1 the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher® DES. A landmark study of groundbreaking devices used to treat coronary artery disease, PROTECT is the first and largest randomized controlled trial (RCT) of its kind.
comments powered by